Moxonidine vs Nitrendipine for Hypertension in Kidney Disease
Author Information
Author(s): Kavi Littlewood, Wolfgang Greiner, Dominique Baum, York Zoellner
Primary Institution: Mapi Values Netherlands BV
Hypothesis
Adjunctive moxonidine may reduce the burden of end-stage renal disease (ESRD) in hypertensive patients with advanced renal failure compared to nitrendipine.
Conclusion
Moxonidine treatment is predicted to significantly reduce new cases of ESRD and provide long-term cost savings compared to nitrendipine.
Supporting Evidence
- Moxonidine reduced the number of ESRD cases by 81% over three years compared to nitrendipine.
- Cumulative costs per patient were significantly lower in the moxonidine group (€9,858) than in the nitrendipine group (€37,472).
- Probabilistic analyses confirmed that the moxonidine strategy was dominant over nitrendipine in over 98.9% of cases.
Takeaway
Using moxonidine instead of nitrendipine can help people with kidney problems live longer and spend less on treatment.
Methodology
A Markov model was used to extrapolate results from a six-month trial over three years.
Potential Biases
The assumption that differences in creatinine clearance decline were not due to other risk factors may introduce bias.
Limitations
The study relied on data from a single six-month trial, and there were missing proteinuria data for 40% of patients.
Participant Demographics
Adult patients with advanced renal failure and hypertension.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI 31.8–45.8 for nitrendipine; 95% CI 3.5–12.7 for moxonidine
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website